دورية أكاديمية
Insights into the molecular profiles of adult and paediatric acute myeloid leukaemia.
| العنوان: | Insights into the molecular profiles of adult and paediatric acute myeloid leukaemia. |
|---|---|
| المؤلفون: | Aung MMK; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, UK., Mills ML; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, UK., Bittencourt-Silvestre J; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, UK., Keeshan K; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, UK. |
| المصدر: | Molecular oncology [Mol Oncol] 2021 Sep; Vol. 15 (9), pp. 2253-2272. Date of Electronic Publication: 2021 Feb 11. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2017- : Hoboken, New Jersey : John Wiley & Sons, Inc. Original Publication: Amsterdam : Elsevier |
| مواضيع طبية MeSH: | Gene Expression Profiling*, Leukemia, Myeloid, Acute/*genetics, Adult ; Biomarkers, Tumor/genetics ; Child ; Drug Resistance, Neoplasm/genetics ; Epigenesis, Genetic ; Humans ; Transcription, Genetic |
| مستخلص: | Acute myeloid leukaemia (AML) is a clinically and molecularly heterogeneous disease characterised by uncontrolled proliferation, block in differentiation and acquired self-renewal of hematopoietic stem and myeloid progenitor cells. This results in the clonal expansion of myeloid blasts within the bone marrow and peripheral blood. The incidence of AML increases with age, and in childhood, AML accounts for 20% of all leukaemias. Whilst there are many clinical and biological similarities between paediatric and adult AML with continuum across the age range, many characteristics of AML are associated with age of disease onset. These include chromosomal aberrations, gene mutations and differentiation lineage. Following chemotherapy, AML cells that survive and result in disease relapse exist in an altered chemoresistant state. Molecular profiling currently represents a powerful avenue of experimentation to study AML cells from adults and children pre- and postchemotherapy as a means of identifying prognostic biomarkers and targetable molecular vulnerabilities that may be age-specific. This review highlights recent advances in our knowledge of the molecular profiles with a focus on transcriptomes and metabolomes, leukaemia stem cells and chemoresistant cells in adult and paediatric AML and focus on areas that hold promise for future therapies. (© 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.) |
| References: | Cancer Cell. 2014 Mar 17;25(3):379-92. (PMID: 24613412) Cell Stem Cell. 2013 Mar 7;12(3):329-41. (PMID: 23333149) Exp Hematol. 2017 Oct;54:40-50. (PMID: 28668350) Leukemia. 2016 Feb;30(2):439-46. (PMID: 26437777) Clin Cancer Res. 2015 Mar 15;21(6):1360-72. (PMID: 25547679) JAMA. 2010 Dec 22;304(24):2706-15. (PMID: 21177505) J Clin Oncol. 2018 Jun 20;36(18):1788-1797. (PMID: 29702001) Blood. 2016 Jan 7;127(1):29-41. (PMID: 26660431) Br J Haematol. 2018 Nov;183(3):512-516. (PMID: 29076143) Cancer Cell. 2010 Jan 19;17(1):13-27. (PMID: 20060365) Nat Med. 2006 Oct;12(10):1167-74. (PMID: 16998484) Clin Pharmacol Ther. 2019 Sep;106(3):544-556. (PMID: 31173340) Leuk Lymphoma. 2015 Apr;56(4):1033-42. (PMID: 25098427) Blood. 2016 Jul 14;128(2):253-64. (PMID: 27257182) Leukemia. 2020 Mar;34(3):735-745. (PMID: 31645648) Blood. 2019 Apr 11;133(15):1630-1643. (PMID: 30803991) Genome Med. 2020 Jan 14;12(1):8. (PMID: 31937368) Blood. 2016 Jan 7;127(1):42-52. (PMID: 26660432) Cell Stem Cell. 2016 Jul 7;19(1):23-37. (PMID: 27374788) Semin Hematol. 2015 Jul;52(3):165-71. (PMID: 26111463) Leukemia. 1994 May;8(5):735-9. (PMID: 7514242) Cancer Discov. 2019 Dec;9(12):1736-1753. (PMID: 31662298) Oncogene. 2020 Feb;39(6):1198-1212. (PMID: 31649334) Cancer Cell. 2018 Sep 10;34(3):483-498.e5. (PMID: 30205048) Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3339-44. (PMID: 16492768) Br J Haematol. 2020 Jan;188(1):49-62. (PMID: 31863468) Cell. 2012 Jul 20;150(2):264-78. (PMID: 22817890) Nat Commun. 2018 Dec 11;9(1):5280. (PMID: 30538250) Br J Haematol. 2016 Nov;175(3):476-489. (PMID: 27470916) Nature. 2017 Jul 6;547(7661):104-108. (PMID: 28658204) Mol Genet Metab. 2020 Aug;130(4):230-238. (PMID: 32457018) N Engl J Med. 2004 Apr 15;350(16):1617-28. (PMID: 15084694) Cancer Res. 2019 Oct 15;79(20):5191-5203. (PMID: 31358527) Blood. 2016 Sep 29;128(13):1671-8. (PMID: 27421961) Nat Genet. 2018 Jun;50(6):895-903. (PMID: 29808029) Cancer Discov. 2017 Jul;7(7):716-735. (PMID: 28416471) J Natl Compr Canc Netw. 2019 Jun 1;17(6):721-749. (PMID: 31200351) Leukemia. 2015 Feb;29(2):312-20. (PMID: 25113226) Best Pract Res Clin Haematol. 2019 Jun;32(2):145-153. (PMID: 31203996) Leukemia. 2019 Aug;33(8):1934-1943. (PMID: 30760869) Haematologica. 2009 Jan;94(1):131-4. (PMID: 18838472) Cancer Cell. 2015 Jun 8;27(6):864-76. (PMID: 26058080) Mol Oncol. 2010 Oct;4(5):443-50. (PMID: 20599449) Nat Med. 2011 Aug 28;17(9):1086-93. (PMID: 21873988) Nat Med. 1997 Jul;3(7):730-7. (PMID: 9212098) Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2548-53. (PMID: 24550281) Blood. 2002 May 15;99(10):3801-5. (PMID: 11986239) Cancer Cell. 2018 Oct 8;34(4):674-689.e8. (PMID: 30245083) Science. 2020 Apr 10;368(6487):. (PMID: 32273439) Stem Cells. 2013 Jul;31(7):1434-45. (PMID: 23592435) Am J Hematol. 2018 Oct;93(10):1267-1291. (PMID: 30328165) Genome Res. 2018 Sep;28(9):1345-1352. (PMID: 30087104) Exp Hematol. 2018 Mar;59:66-71.e4. (PMID: 29253573) Cells. 2019 Aug 24;8(9):. (PMID: 31450562) Expert Rev Hematol. 2017 Jun;10(6):563-574. (PMID: 28475434) Nat Rev Cancer. 2020 May;20(5):285-298. (PMID: 32112045) Cell. 2012 Jun 8;149(6):1284-97. (PMID: 22632761) Cell Stem Cell. 2018 Jul 05;23(1):86-100.e6. (PMID: 29910151) Cell. 2019 Mar 7;176(6):1265-1281.e24. (PMID: 30827681) Blood. 2015 Jul 16;126(3):291-9. (PMID: 25987659) N Engl J Med. 2013 May 30;368(22):2059-74. (PMID: 23634996) Cancer Cell. 2018 Nov 12;34(5):724-740.e4. (PMID: 30423294) Cancer Cell. 2019 Aug 12;36(2):123-138.e10. (PMID: 31303423) Blood. 2015 Mar 26;125(13):2120-30. (PMID: 25631767) Blood. 2005 Jun 1;105(11):4163-9. (PMID: 15687234) N Engl J Med. 2016 Jun 9;374(23):2209-2221. (PMID: 27276561) Blood. 2015 Nov 26;126(22):2491-501. (PMID: 26438511) Ther Adv Hematol. 2019 Jul 10;10:2040620719860645. (PMID: 31321011) Nature. 2018 Oct;562(7728):526-531. (PMID: 30333627) Int J Hematol. 2020 Jun;111(6):761-770. (PMID: 32056080) Cell Stem Cell. 2013 Aug 1;13(2):161-74. (PMID: 23910083) Early Hum Dev. 2005 Jan;81(1):123-9. (PMID: 15707724) Exp Hematol. 2015 Sep;43(9):745-55. (PMID: 26051919) Blood. 2016 May 19;127(20):2391-405. (PMID: 27069254) Nat Biotechnol. 2010 Mar;28(3):275-80. (PMID: 20160717) Cell Stem Cell. 2015 Oct 1;17(4):412-21. (PMID: 26387756) Cells. 2019 Jul 31;8(8):. (PMID: 31370337) Haematologica. 2011 Feb;96(2):221-30. (PMID: 20971820) Leukemia. 2019 Feb;33(2):348-357. (PMID: 30089916) Ann Oncol. 2020 Jun;31(6):697-712. (PMID: 32171751) Blood. 2014 Sep 4;124(10):1645-54. (PMID: 25006128) Blood. 2009 Oct 1;114(14):3001-7. (PMID: 19666867) Semin Hematol. 2019 Apr;56(2):90-95. (PMID: 30926096) Dis Model Mech. 2014 Aug;7(8):941-51. (PMID: 25056697) Cancer Res. 2016 Apr 15;76(8):2197-205. (PMID: 26941285) Blood Cancer J. 2018 Jun 6;8(6):52. (PMID: 29921955) Front Pediatr. 2019 Oct 15;7:401. (PMID: 31681706) J Clin Oncol. 2017 Dec 10;35(35):3964-3977. (PMID: 29068783) Nat Med. 2018 Jan;24(1):103-112. (PMID: 29227476) N Engl J Med. 2009 Sep 10;361(11):1058-66. (PMID: 19657110) Sci Rep. 2018 Apr 3;8(1):5534. (PMID: 29615816) Blood. 2017 Jan 26;129(4):424-447. (PMID: 27895058) Nat Genet. 2013 Oct;45(10):1113-20. (PMID: 24071849) Blood Adv. 2018 Nov 13;2(21):3070-3080. (PMID: 30425072) Nat Biotechnol. 2007 Nov;25(11):1315-21. (PMID: 17952057) Front Oncol. 2019 May 22;9:405. (PMID: 31192118) EBioMedicine. 2019 Sep;47:221-234. (PMID: 31473184) Blood. 2004 Dec 1;104(12):3679-87. (PMID: 15226186) Nat Cell Biol. 2017 Nov;19(11):1336-1347. (PMID: 29035359) Br J Haematol. 2017 Jan;176(1):86-91. (PMID: 27766616) Sci Transl Med. 2015 Apr 1;7(281):281re2. (PMID: 25834112) Exp Hematol. 2018 Jul;63:1-11. (PMID: 29608923) Cell Stem Cell. 2014 Mar 6;14(3):275-91. (PMID: 24607403) Leukemia. 2018 Jul;32(7):1598-1608. (PMID: 29472724) Br J Haematol. 2018 Jul;182(2):170-184. (PMID: 29806701) Leukemia. 2017 Oct;31(10):2143-2150. (PMID: 28194038) Nature. 2016 Dec 15;540(7633):433-437. (PMID: 27926740) Sci Rep. 2019 Jan 30;9(1):1007. (PMID: 30700727) Clin Cancer Res. 2020 Feb 1;26(3):726-737. (PMID: 31719049) Blood. 2000 Sep 15;96(6):2108-15. (PMID: 10979955) Mol Cancer Ther. 2015 Oct;14(10):2364-73. (PMID: 26206337) Nat Rev Cancer. 2020 Mar;20(3):158-173. (PMID: 31907378) N Engl J Med. 2014 Dec 25;371(26):2488-98. (PMID: 25426837) Nature. 2018 Jul;559(7714):400-404. (PMID: 29988082) Nat Commun. 2019 Nov 1;10(1):4986. (PMID: 31676777) Nat Med. 2018 Jul;24(7):1015-1023. (PMID: 29988143) Leukemia. 2017 Nov;31(11):2288-2302. (PMID: 28193998) Nat Commun. 2016 Aug 18;7:12475. (PMID: 27534895) Science. 2006 Sep 29;313(5795):1929-35. (PMID: 17008526) Nature. 2012 Jan 11;481(7382):506-10. (PMID: 22237025) Blood. 2018 Mar 22;131(12):1275-1291. (PMID: 29330221) |
| فهرسة مساهمة: | Keywords: acute myeloid leukaemia; adult; chemoresistance; clonality; omic profiling; paediatric |
| المشرفين على المادة: | 0 (Biomarkers, Tumor) |
| تواريخ الأحداث: | Date Created: 20210109 Date Completed: 20220328 Latest Revision: 20231107 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC8410545 |
| DOI: | 10.1002/1878-0261.12899 |
| PMID: | 33421304 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1878-0261 |
|---|---|
| DOI: | 10.1002/1878-0261.12899 |